Vascular Dementia (VaD) represents the second most common cause of dementia after Alzheimer's disease, accounting for approximately 15-20% of all dementia cases. Unlike AD which primarily targets neurons through proteinopathy, VaD results from cerebrovascular pathology that disrupts blood flow to the brain through infarction, hypoperfusion, or hemorrhagic events. This combination therapy concept addresses the multi-factorial nature of VaD by simultaneously targeting vascular risk factors, neuroprotection, and cerebral perfusion enhancement—the three pillars of effective VaD treatment.
Mechanism of Action
The Vascular Cognitive Impairment Triad
VaD involves three interconnected pathophysiological axes that require simultaneous therapeutic intervention:
Vascular risk factor-driven injury - Hypertension, diabetes, hyperlipidemia, and atrial fibrillation cause progressive cerebrovascular damage through large vessel atherosclerosis, small vessel disease, and cardioembolic events.
Chronic hypoperfusion - Reduced cerebral blood flow leads to white matter lesions, subcortical damage, and impaired glucose metabolismparticularly affecting frontostriatal circuits.
Neurotransmitter disruption - Damage to cholinergic pathways running through white matter and subcortical regions causes cognitive deficits independent of primary neuronal loss.
Therapeutic Target Stack
This combination therapy combines three complementary approaches:
Pillar 1: Vascular Risk Factor Modulation
Aggressive blood pressure control (target <130/80 mmHg)
Lipid management with high-intensity statins
Diabetes optimization (HbA1c <7%)
Antiplatelet/anticoagulation therapy as indicated
Pillar 2: Neuroprotection
Cholinesterase inhibitors (donepezil, rivastigmine) for cholinergic restoration
Single-pillar approaches have shown limited efficacy in VaD because:
Antiplatelets alone do not restore cognitive function
Cholinesterase inhibitors alone do not prevent progression
Blood pressure control alone does not repair existing damage
The combination addresses both preventing further injury AND treating existing cognitive deficits through complementary mechanisms. This mirrors successful combination approaches in other complex dementias.
Rubric Scores
| Dimension | Score | Rationale | |-----------|-------|-----------| | Novelty | 7 | Novel multi-target integration for VaD - existing individual components validated | | Mechanistic Rationale | 9 | Strong rationale - all three pillars independently validated in VaD | | Addresses Root Cause | 9 | Targets both preventing progression and treating symptoms | | Delivery Feasibility | 8 | All components are approved or in development; existing delivery infrastructure | | Safety Plausibility | 8 | Each component has established safety profile; combination monitoring feasible | | Combinability | 9 | Components target distinct mechanisms with minimal overlap | | Biomarker Availability | 8 | MRI lesion burden, CBF, cognitive batteries can track response | | De-risking Path | 8 | Each component individually de-risked; combination trials feasible |
Total: 74/100
Disease Coverage
| Disease | Coverage | Rationale | |---------|----------|-----------| | Vascular Dementia | 10 | Primary target - addresses all three VaD pillars | | Alzheimer's Disease | 7 | Mixed dementia - vascular component common | | Post-Stroke Dementia | 10 | Directly addresses stroke-related cognitive impairment | | Mixed Dementia | 9 | Addresses both AD and VaD components | | Aging | 7 | Addresses vascular contributions to age-related cognitive decline | | Cerebral Small Vessel Disease | 10 | Directly targets small vessel pathology |
Implementation Strategy
Phase 1: Component Integration
Establish therapeutic targets for each pillar
Identify optimal dosing schedules
Develop monitoring protocols
Phase 2: Combination Optimization
Test pillar-component combinations
Optimize sequencing (e.g., BP control first, then neuroprotection)